#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
Tirzepatide vs semaglutide: real-world data
A 511-patient real-world study in Mayo Clinic Proceedings found tirzepatide produced 16.6% vs 13.4% mean weight loss for semaglutide over 12 months.
Bofanglutide vs semaglutide in Chinese T2D
Ann Intern Med Phase 2b: bofanglutide 18 mg biweekly cut HbA1c by 2.28 points versus 1.60 for semaglutide 1 mg weekly in Chinese patients with type 2 diabetes.
CagriSema pen usability: the study results
A 150-person study tested whether adults with overweight or diabetes could use the CagriSema dual-chamber autoinjector correctly after 3 minutes of training.
GLP-1 drugs in Medicaid: the coverage gap
Most US Medicaid programs restrict or exclude GLP-1 obesity drugs. Here is what the research says about who gets access and why coverage varies by state.
Health Canada vs FDA: approval paths
A 2026 JGIM study compares how Health Canada and the FDA use expedited pathways, with implications for Canadian patients waiting on GLP-1 approvals.
Semaglutide P29: a new production method
A 2026 PLoS ONE study reports 5.85 g/L yield and 98% purity for the semaglutide main-chain intermediate using a SNAC-tagged bacterial expression system.
Semaglutide and diabetes recovery stories
A 2026 medical humanities paper asks what happens to patient recovery narratives when semaglutide does much of the biological work.
Semaglutide and weight in schizophrenia
A 24-week trial found semaglutide reduced body weight by 9.8% in people with schizophrenia on clozapine or olanzapine, with partial regain after stopping.
GLP-1 drugs and mental health: a 2026 study
A June 2026 cohort study found lower rates of anxiety and depression in adults on tirzepatide or semaglutide vs other weight-loss drugs, and what that means.
Tirzepatide and steatotic liver disease
A 2026 real-world study finds tirzepatide cut major liver complications and mortality in adults with steatotic liver disease and cardiometabolic dysfunction.